Description
Tecentriq (Atezolizumab) is a medication that belongs to the class of immunotherapy drugs. It is designed to treat advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (bladder cancer).
Mechanism of Action:
Tecentriq works by blocking the activity of a protein known as PD-L1. This protein is responsible for suppressing the immune system by signaling immune cells to stop attacking cancer cells. By blocking PD-L1, Tecentriq helps the immune system attack and destroy cancer cells, leading to tumor shrinkage.
Uses:
Tecentriq is approved for use in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (bladder cancer).
Storage Conditions:
Tecentriq should be stored in a refrigerator at a temperature of 2°C to 8°C until it is used. It should be protected from light and not be frozen. Once the medication is removed from the refrigerator, it may be stored at room temperature (15°C to 30°C) for up to 48 hours.
HOW TO USE:
Tecentriq is administered intravenously (IV) over a period of 60 minutes. The dosage and frequency of administration depend on the type of cancer and the patient’s medical condition. Tecentriq is given as a series of treatments until the cancer is under control or the patient experiences side effects that require discontinuation of the drug.
Precautions:
Before starting Tecentriq, patients should inform their doctor of any allergies, medical conditions, or medications they are taking. Patients who have had an organ transplant or who are receiving immunosuppressive drugs should not take Tecentriq. Females who are pregnant or breastfeeding should not take Tecentriq.
Drug Interactions:
Tecentriq is not known to interact with other drugs. However, patients should inform their doctor of any medications they are taking, including prescription, over-the-counter, and herbal remedies.
Contraindications:
Tecentriq should not be taken by patients who are allergic to atezolizumab or any of the other ingredients in the medication. Patients who have had an organ transplant or who are receiving immunosuppressive drugs should not take Tecentriq. Females who are pregnant or breastfeeding should not take Tecentriq.
Overdose:
No information is available on the effects of a Tecentriq overdose. However, patients who receive too much of the drug should inform their doctor immediately.
Adverse Reactions:
The most common side effects of Tecentriq include fatigue, nausea, cough, decreased appetite, and constipation. More severe side effects may include trouble breathing, liver problems, and inflammation of the lungs. Patients should inform their doctor immediately if they experience any unusual symptoms while taking Tecentriq.
Reviews
There are no reviews yet.